Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Indication, By End User, By Region and Competition, 2020-2030F

Description

Global Cancer Gene Therapy Market was valued at USD 4.52 billion in 2024 and is expected to reach USD 13.58 billion by 2030 with a CAGR of 20.12% during the forecast period. The global market for Cancer Gene Therapy is experiencing significant growth, driven by the growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increase the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about advantages of using gene therapy and diagnosis along with increasing healthcare expenditure on cancer treatment across the globe is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States. Cancer is one of the deadliest diseases in the world, and it has been a significant concern for public health for decades.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.52 Billion
Market Size 2030	USD 13.58 Billion
CAGR 2025-2030	20.12%
Fastest Growing Segment	Lung Cancer
Largest Market	North America

Key Market Drivers

Rising Global Cancer Burden and Need for Precision Therapies

The rising global burden of cancer is a fundamental driver of the cancer gene therapy market. According to the World Health Organization (WHO), cancer is a leading cause of death globally, responsible for nearly 10 million deaths in 2020. The most common forms include lung, breast, colorectal, prostate, and stomach cancer. Traditional treatments like chemotherapy and radiation often have systemic toxicity and variable efficacy, particularly in advanced-stage or genetically complex tumors. Gene therapy offers a transformative approach to cancer treatment by directly targeting the genetic root of disease-whether through inserting therapeutic genes, editing faulty ones, or using viral vectors to trigger immune responses. This is especially critical in cancers where oncogenic mutations drive resistance to conventional therapies.

The U.S. National Cancer Institute (NCI) and similar institutions in Europe and Asia are significantly increasing funding for precision medicine and gene-based oncology research. In the U.S., the 21st Century Cures Act and initiatives like the Cancer Moonshot have allocated billions toward advanced cancer research, including gene therapy. As the prevalence of cancer continues to climb due to aging populations and environmental exposures, the demand for targeted and durable treatments like gene therapy is expected to rise. These therapies not only promise improved survival outcomes but also offer the potential for long-term remission or even cures, particularly in genetically defined cancers like hematological malignancies or glioblastomas.

Key Market Challenges

High Cost and Limited Access to Gene Therapy

One of the primary challenges facing the global cancer gene therapy market is the high cost of treatment and the resultant limited patient access, particularly in low- and middle-income countries. Gene therapy, especially when customized for individuals, requires sophisticated manufacturing processes, skilled personnel, and stringent regulatory compliance, all of which contribute to its premium price. Approved therapies like CAR-T treatments have been priced between $350,000 to $500,000 per patient in markets like the U.S. and Europe. This cost does not account for hospitalization, supportive care, or follow-up, making the overall financial burden even higher. These prices place a significant strain on healthcare systems, especially those that operate on public insurance or low reimbursement thresholds.

Government health agencies, including the U.S. Centers for Medicare & Medicaid Services (CMS), have explored reimbursement models like outcomes-based pricing to make these therapies more sustainable. However, in many parts of Asia, Africa, and Latin America, such policies are either underdeveloped or non-existent, preventing wider adoption of gene therapy innovations. The affordability issue becomes more complex when considering the need for lifelong monitoring and potential retreatment. As gene therapies are still in the early stage of commercialization, cost reduction through economies of scale has not yet materialized. Until these therapies become more economically viable and globally accessible, their impact on global cancer care will remain uneven.

Key Market Trends

Expansion of Personalized Cancer Gene Therapy

A major trend in the global cancer gene therapy market is the movement toward highly personalized medicine. Advances in genomics and next-generation sequencing (NGS) have enabled detailed characterization of cancer at the molecular level, identifying specific genetic mutations, epigenetic modifications, and biomarkers. This data is being used to tailor gene therapies uniquely suited to individual patients' tumor profiles. For instance, gene-editing platforms like CRISPR-Cas9 are now being explored to create bespoke cancer therapies, where genes are selectively silenced or corrected. Similarly, personalized CAR-T cell therapies-where a patient's T-cells are genetically modified to recognize tumor-specific antigens-have already shown success in treating refractory blood cancers like leukemia and lymphoma.

Global governments are actively investing in precision oncology. For example, the U.K. has launched the Genomic Medicine Service within the NHS, integrating whole genome sequencing into cancer diagnosis and treatment planning. In the United States, the Precision Medicine Initiative supports integrating molecular data into clinical care, including gene therapy applications. This trend signifies a shift from the "one-size-fits-all" treatment paradigm to customized interventions with potentially fewer side effects and higher therapeutic success. As genomic profiling becomes more accessible, the scope for personalized gene therapy will continue to expand, reshaping the way cancer is treated across various demographics and geographies.

Key Market Players

Abeona Therapeutics Inc.
Asklepios BioPharmaceutical Inc.
Altor Bioscience Inc.
BioCancell Inc.
Celgene Inc.
Elevate Bio Inc.
Genelux Corporation
Introgen Therapeutics Inc.
OncoGenex Pharmaceuticals Inc.
Merck KGaA

Report Scope:

In this report, the Global Cancer Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Gene Therapy Market, By Therapy:

Oncolytic Virotherapy
Gene Induced Immunotherapy
Gene Transfer
Others

Cancer Gene Therapy Market, By Indication:

Breast Cancer
Ovarian Cancer
Lung Cancer
Liver Cancer
Pancreatic Cancer
Prostate Cancer
Others

Cancer Gene Therapy Market, By End User:

Biotechnology & Pharmaceutical Companies
Academic & Research Institutions
Others

Cancer Gene Therapy Market, By Region:

North America
- United States
- Mexico
- Canada
Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
South America
- Brazil
- Argentina
- Colombia
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cancer Gene Therapy Market.

Available Customizations:

Global Cancer Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map

6. Global Cancer Gene Therapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, Others)
- 6.2.2. By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, Others)
- 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
- 6.2.4. By Region
- 6.2.5. By Company (2024)
6.3. Market Map

7. North America Cancer Gene Therapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Therapy
- 7.2.2. By Indication
- 7.2.3. By End User
- 7.2.4. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Cancer Gene Therapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapy
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By End User
- 7.3.2. Canada Cancer Gene Therapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapy
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By End User
- 7.3.3. Mexico Cancer Gene Therapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapy
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By End User

8. Europe Cancer Gene Therapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Therapy
- 8.2.2. By Indication
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Europe: Country Analysis
- 8.3.1. France Cancer Gene Therapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapy
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By End User
- 8.3.2. Germany Cancer Gene Therapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapy
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By End User
- 8.3.3. United Kingdom Cancer Gene Therapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapy
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By End User
- 8.3.4. Italy Cancer Gene Therapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapy
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By End User
- 8.3.5. Spain Cancer Gene Therapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapy
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By End User

9. Asia-Pacific Cancer Gene Therapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapy
- 9.2.2. By Indication
- 9.2.3. By End User
- 9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Cancer Gene Therapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapy
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By End User
- 9.3.2. India Cancer Gene Therapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapy
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By End User
- 9.3.3. Japan Cancer Gene Therapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapy
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By End User
- 9.3.4. South Korea Cancer Gene Therapy Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Therapy
    - 9.3.4.2.2. By Indication
    - 9.3.4.2.3. By End User
- 9.3.5. Australia Cancer Gene Therapy Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Therapy
    - 9.3.5.2.2. By Indication
    - 9.3.5.2.3. By End User

10. South America Cancer Gene Therapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapy
- 10.2.2. By Indication
- 10.2.3. By End User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Cancer Gene Therapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapy
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By End User
- 10.3.2. Argentina Cancer Gene Therapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapy
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By End User
- 10.3.3. Colombia Cancer Gene Therapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapy
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By End User

11. Middle East and Africa Cancer Gene Therapy Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Therapy
- 11.2.2. By Indication
- 11.2.3. By End User
- 11.2.4. By Country
11.3. MEA: Country Analysis
- 11.3.1. South Africa Cancer Gene Therapy Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Therapy
    - 11.3.1.2.2. By Indication
    - 11.3.1.2.3. By End User
- 11.3.2. Saudi Arabia Cancer Gene Therapy Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Therapy
    - 11.3.2.2.2. By Indication
    - 11.3.2.2.3. By End User
- 11.3.3. UAE Cancer Gene Therapy Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Therapy
    - 11.3.3.2.2. By Indication
    - 11.3.3.2.3. By End User

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches

14. Competitive Landscape

14.1. Abeona Therapeutics Inc.
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Asklepios BioPharmaceutical Inc.
14.3. Altor Bioscience Inc.
14.4. BioCancell Inc.
14.5. Celgene Inc.
14.6. Elevate Bio Inc.
14.7. Genelux Corporation
14.8. Introgen Therapeutics Inc.
14.9. OncoGenex Pharmaceuticals Inc.
14.10. Merck KGaA